Roche to file Herceptin for stomach cancer after survival benefit shown in Phase III
19 March 2009
Malini Guha
Roche/Genentech's HER2-targeted breast cancer drug Herceptin (trastuzumab) has improved overall survival in a first-line Phase III trial in a subset of patients with advanced gastric (stomach) cancer, and Roche told Scrip that it plans to file the drug for this new indication.
...
Please Login to read the full article.
19 March 2009
Malini Guha
...
Please Login to read the full article.
RELATED CONTENT
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
